

Donghai Dai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7023110/publications.pdf>

Version: 2024-02-01

33
papers

1,089
citations

394421

19
h-index

395702

33
g-index

33
all docs

33
docs citations

33
times ranked

1290
citing authors

#	ARTICLE	IF	CITATIONS
1	G Protein-Coupled Estrogen Receptor-Selective Ligands Modulate Endometrial Tumor Growth. <i>Obstetrics and Gynecology International</i> , 2013, 2013, 1-17.	1.3	126
2	Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. <i>Cancer Research</i> , 2002, 62, 881-6.	0.9	117
3	Gestational trophoblastic diseases: 1. Pathophysiology of hyperglycosylated hCG. <i>Gynecologic Oncology</i> , 2006, 102, 145-150.	1.4	78
4	TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. <i>International Journal of Oncology</i> , 2015, 46, 607-618.	3.3	62
5	Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003, 87, 123-131.	2.5	53
6	Identification of a novel mechanism of NF- κ B inactivation by progesterone through progesterone receptors in Hec50co poorly differentiated endometrial cancer cells: induction of A20 and ABIN-2. <i>Gynecologic Oncology</i> , 2004, 94, 463-470.	1.4	53
7	Progesterone receptor isoform identification and subcellular localization in endometrial cancer. <i>Gynecologic Oncology</i> , 2005, 96, 32-41.	1.4	53
8	Preclinical Development of a Neutral, Estrogen Receptor-Targeted, Tridentate ^{99m} Tc(I)-Estradiol-Pyridin-2-yl Hydrazine Derivative for Imaging of Breast and Endometrial Cancers. <i>Journal of Nuclear Medicine</i> , 2008, 49, 978-986.	5.0	48
9	Molecular tools to reestablish progestin control of endometrial cancer cell proliferation. <i>American Journal of Obstetrics and Gynecology</i> , 2001, 184, 790-797.	1.3	44
10	Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer. <i>Oncotarget</i> , 2014, 5, 9783-9797.	1.8	38
11	Development of a phylogenetic tree model to investigate the role of genetic mutations in endometrial tumors. <i>Oncology Reports</i> , 2011, 25, 1447-54.	2.6	34
12	Stromal Cell Progesterone and Estrogen Receptors during Proliferation and Regression of the Decidua Basalis in the Pregnant Rat1. <i>Biology of Reproduction</i> , 1997, 57, 495-506.	2.7	33
13	Inverse Relationship between Progesterone Receptor and Myc in Endometrial Cancer. <i>PLoS ONE</i> , 2016, 11, e0148912.	2.5	33
14	Regression of the Decidualized Mesometrium and Decidual Cell Apoptosis Are Associated with a Shift in Expression of Bcl2 Family Members1. <i>Biology of Reproduction</i> , 2000, 63, 188-195.	2.7	32
15	Immunomodulatory and Transcriptional Effects of Progesterone Through Progesterone A and B Receptors in Hec50co Poorly Differentiated Endometrial Cancer Cells. <i>Journal of the Society for Gynecologic Investigation</i> , 2004, 11, 494-499.	1.7	30
16	A Potential Synergistic Anticancer Effect of Paclitaxel and Amifostine on Endometrial Cancer. <i>Cancer Research</i> , 2005, 65, 9517-9524.	0.9	29
17	Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53. <i>Gynecologic Oncology</i> , 2013, 128, 461-469.	1.4	29
18	Regulation of the Progesterone Receptor and Estrogen Receptor in Decidua Basalis by Progesterone and Estradiol during Pregnancy1. <i>Biology of Reproduction</i> , 1998, 58, 1188-1198.	2.7	27

#	ARTICLE	IF	CITATIONS
19	Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance. <i>Oncology Reports</i> , 2011, 25, 855-62.	2.6	24
20	Progesterone and Estrogen Regulation of Rat Decidual Cell Expression of Proliferating Cell Nuclear Antigen1. <i>Biology of Reproduction</i> , 1998, 59, 444-450.	2.7	21
21	Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices. <i>Gynecologic Oncology</i> , 2016, 140, 152-160.	1.4	18
22	Progesterone Regulation of Epidermal Growth Factor Receptor in Rat Decidua Basalis during Pregnancy1. <i>Biology of Reproduction</i> , 1999, 61, 326-332.	2.7	17
23	A therapeutic model for advanced endometrial cancer: systemic progestin in combination with local adenoviral-mediated progesterone receptor expression. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 169-75.	4.1	17
24	Gene regulation profiles by progesterone and dexamethasone in human endometrial cancer Ishikawa H cells. <i>Gynecologic Oncology</i> , 2006, 101, 62-70.	1.4	16
25	miR-888: A Novel Cancer-Testis Antigen that Targets the Progesterone Receptor in Endometrial Cancer. <i>Translational Oncology</i> , 2015, 8, 85-96.	3.7	15
26	MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 2019, 155, 349-358.	1.4	15
27	Progesterone-regulated determinants of stromal cell survival and death in uterine decidua are linked to protein kinase C activity1. <i>Steroids</i> , 1999, 64, 628-633.	1.8	10
28	Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations. <i>Gynecologic Oncology</i> , 2016, 142, 150-157.	1.4	6
29	Genetic Diversity in Normal Cell Populations is the Earliest Stage of Oncogenesis Leading to Intra-Tumor Heterogeneity. <i>Frontiers in Oncology</i> , 2013, 3, 61.	2.8	4
30	Loss of progesterone receptor through epigenetic regulation is associated with poor prognosis in solid tumors. <i>American Journal of Cancer Research</i> , 2020, 10, 1827-1843.	1.4	3
31	Quantitative Interpretation of a Genetic Model of Carcinogenesis Using Computer Simulations. <i>PLoS ONE</i> , 2011, 6, e16859.	2.5	2
32	Predictors of immunotherapeutic benefits in patients with advanced melanoma and other malignancies treated with immune checkpoint inhibitors utilizing ORIEN "real-world" data.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2618-2618.	1.6	1
33	A deep learning approach utilizing clinical and molecular data for identifying prognostic biomarkers in patients treated with immune checkpoint inhibitors: An ORIEN pan-cancer study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2619-2619.	1.6	1